FDA tightens label on antibody-drug conjugate, Adcetris

Just six months after approving Adcetris (brentuximab vedotin), the US Food and Drug Administration has announced that the developer, Seattle Genetics Inc, will be tightening the drug’s label to warn against the rare PML brain infection.